Medrx Co

Medrx Co Stock-Based Compensation

The Stock-Based Compensation (SBC) of Medrx Co (4586.T) as of Nov 19, 2026 is 12.07 M JPY. In the previous year, Stock-Based Compensation (SBC) was 9.43 M JPY — a change of 27.99% (higher).

Stock-Based Compensation

12.07 MJPY

YoY

27.99%

Last updated:

Stock-Based Compensation (SBC) of Medrx Co is 2025 12.07 M JPY. Stock-Based Compensation (SBC) of Medrx Co was 2024 9.43 M JPY. It decreases by 27.99% higher compared to the previous year.

The Medrx Co Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2020
7.25 M JPY
Jan 1, 2021
8.26 M JPY
Jan 1, 2022
5.25 M JPY
Jan 1, 2023
4.19 M JPY
Jan 1, 2024
9.43 M JPY
Jan 1, 2025
12.07 M JPY
The Medrx Co Stock-Based Compensation history
YEARStock-Based CompensationYoY
12.07 MJPY+27.99%
9.43 MJPY+124.90%
4.19 MJPY-20.14%
5.25 MJPY-36.46%
8.26 MJPY+14.02%
7.25 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medrx Co Stock analysis

What does Medrx Co do? Medrx Co. Ltd. develops pharmaceutical drugs using transdermal absorption technology, focusing on percutaneous absorption through ionic liquid transdermal system (ILTS) and nano-sized colloid transdermal system (NCTS). The company aims to maximize drug efficacy, reduce side effects, and provide alternatives for patients who cannot take oral medications. Its products target new markets by offering medicines with enhanced delivery systems and added value. The firm's technology includes ionic liquid transdermal system (ILTS) leveraging ionic liquid characteristics and nano-sized colloid transdermal system (NCTS) utilizing nano colloidization technology. These systems enable precise drug delivery, addressing challenges in oral administration and improving patient compliance. The company's products are designed to serve patients requiring non-oral medication options. Medrx Co. Ltd. produces medicines based on percutaneous absorption formulation technology, targeting healthcare providers and patients who need alternative drug administration methods. The company's focus on transdermal systems allows it to address specific medical needs, such as preventing forgotten doses and reducing side effects associated with traditional oral drugs. Medrx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medrx Co stock

Stock-Based Compensation (SBC) of Medrx Co is 12.07 M JPY in 2025.

Stock-Based Compensation (SBC) of Medrx Co changed from 9.43 M JPY to 12.07 M JPY, representing a 27.99% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Medrx Co since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Medrx Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Medrx Co

All Key Metrics — Medrx Co